Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 17, 2025

Keywords

ClinConnect Summary

The clinical trial titled "Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients" is looking to improve how we diagnose a serious lung infection called Pneumocystis pneumonia (PcP) in patients whose immune systems are weakened. Researchers want to test a new diagnostic method that uses a special technique called qPCR on easy-to-collect samples, like saliva or mucus, instead of more invasive procedures that require a bronchoscopy. This study aims to see if these new methods can accurately identify the infection compared to traditional testing methods.

To participate in this trial, adult patients aged 65 and older who have symptoms suggesting Pneumocystis pneumonia and need a bronchial procedure for testing may be eligible. Participants should not have been treated for Pneumocystis for more than 72 hours and must be able to give consent or have their family support their participation. While the study is not yet recruiting participants, those who join can expect to help researchers understand better ways to diagnose this infection, potentially leading to quicker and safer testing methods for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patients with suspected pneumocystis
• • with an indication for bronchial fibroscopy for BAL or induced sputum
• • no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition
• Exclusion Criteria:
• • Pneumocystis treated for more than 72 hours
• • pregnancy/breast-feeding
• • adult patients deprived of liberty, protected